Trial Profile
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5ug and 5ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms GraziaTinA-asthma
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 02 Jul 2019 Results of pooled analysis of 12 studies (NCT01634113, NCT01634139, NCT01634152, NCT01257230, NCT01277523, NCT01316380, NCT00350207, NCT01172808, NCT01172821, NCT01340209, NCT00772538 and NCT00776984) assessing safety of Tiotropium bromide as an add-on option to inhaled corticosteroids in pediatric and adult black or African-American patients with asthma, published in the Respiratory Medicine.
- 05 Mar 2018 Results of post hoc analysis from five double-blind, placebo-controlled trials (GraziaTinA-asthma, MezzoTinA-asthma, PrimoTinA-asthma) presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 24 May 2017 Results of clinical outcome data from five phase III studies (GraziaTinA-asthma, MezzoTinA-asthma-1, MezzoTinA-asthma-2, RubaTinA-asthma and PensieTinA-asthma) presented at the 113th International Conference of the American Thoracic Society